ClinicalTrials.gg
CompletedNCT02606760Updated Mar 8, 2018

Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis

A Phase 3 interventional study of P-3073 and Vehicle of P-3073 in Nail Psoriasis, sponsored by Polichem S.A.. Completed at 7 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-03-08.

Sponsored by Polichem S.A. (part of Almirall, S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Psoriasis by Almirall, S.A. — 2 open to participants now, 3 under way, none of them phase 3. Psoriasis · Almirall, S.A..

Enrollment
2nd of 14
378 · median 36
Started
2015
the only one that year
Phase 3
3 of 20
none open now
Registered
9th of 20
by date

Among the 20 studies in Psoriasis by Almirall, S.A., this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2015, is one of 3 in phase 3, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 20 studies in Psoriasis by Almirall, S.A. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Psoriasis by Almirall, S.A., or all of them as a file.
02

Study summary

The purpose of this study is to confirm the clinical efficacy and the safety of P-3073 in patients affected by isolated psoriatic nail(s) and/or those with psoriatic nails and concomitant mild to moderate plaque psoriasis.

03

Conditions studied

  • Nail Psoriasis

Browse trials for

Keywords

  • Nail psoriasis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written before starting any study related procedures
  • Patients aged 18 to 80 years old of any race.
  • Males or females.
  • Patients with mild to moderate psoriastic fingernail(s) defined as fingernail/s with matrix psoriasis NAPSI score and/or bed psoriasis NAPSI score ≥ 1 and ≤ 3 at baseline.
  • In case of skin involvement, patients with established clinical diagnosis of mild-to-moderate psoriasis (BSA involvement ≤ 8% or PASI ≤ 10)

Exclusion criteria

Exclusion Criteria:

  • Woman who is pregnant, nursing an infant, or planning a pregnancy during the study period.
  • Use of any systemic treatment for psoriasis during the last six months before the screening visit.
  • Use of photochemotherapy or other forms of radiotherapy during the last four weeks before the screening visit.
  • Positive mycology findings
  • Systemic use of immunosuppressives, chemotherapy and during last three months before the screening visit.
  • Consumption of Vitamin D or its analogues during the last three months.
  • History of hypercalcaemia or hypercalciuria.
  • infection or any other immunodeficiency.
  • Alcohol or substance abuse.
  • Patients with history of allergic reactions to calcipotriol or its .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
378 participants (actual)

Study arms

  • Experimental
    P-3073

    P-3073

    Drug: P-3073

  • Placebo comparator
    vehicle of P-3073

    vehicle of P-3073

    Drug: Vehicle of P-3073

Interventions

  • DrugP-3073
  • DrugVehicle of P-3073
06

What researchers measure

Primary outcomes

  1. Change in total Nail Psoriasis Severity Index (NAPSI)

    Time frame: Baseline - Week 24

Secondary outcomes

  1. Change in NAPSI matrix

    Time frame: Baseline - Week 24

  2. Change in NAPSI bed

    Time frame: Week 24

  3. Nail Physician Global Assessment (PGA) response rate

    Time frame: Week 24

  4. Change in patient's quality-of-life by means of the Dermatology Life Quality Index (DLQI)

    Time frame: Baseline - Week 24

  5. Change in discomfort by means of the Visual Analogue Scale (VAS)

    Time frame: Week 24

  6. Proportions of nails with improvement in total NAPSI

    Time frame: Week 24

  7. Proportions of nails with improvement in NAPSI Matrix

    Time frame: Week 24

  8. Proportions of nails with improvement in NAPSI bed

    Time frame: Week 24

  9. Overall safety by recording any AE during the entire study duration and the local tolerability by means of severity scores for skin irritation.

    Time frame: Week 24

07

Study locations

7 sites
  • Multiple Locations, Bulgaria
  • Multiple Locations, Czechia
  • Multiple Locations, Germany
  • Multiple Locations, Greece
  • Multiple Locations, Latvia
  • Multiple Locations, Poland
  • Multiple Locations, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Feb 2017, 14 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2015
First posted
Nov 17, 2015
StartActual
Nov 23, 2015
Primary completionActual
Feb 8, 2017
CompletionActual
Feb 8, 2017
Last update
Mar 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02606760
Lead sponsor
Polichem S.A.
Responsible party
Sponsor
First posted
Nov 17, 2015
Start date
Nov 23, 2015
Primary completion
Feb 8, 2017
Completion
Feb 8, 2017
Last update
Mar 8, 2018

Study contacts

Maurizio Caserini, MD
study director · Polichem S.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion